Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
Not Available
II
Davis, Nancy
NCT03459846
VICCURO1880

Study of GBR 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.
Multiple Myeloma
I
Cornell, Robert
NCT03309111
VICCHEMP17111

Ruxolitinib Phosphate in Treating Older Patients with Acute Myeloid Leukemia in First Complete Remission after Donor Stem Cell Transplant

Multiple Cancer Types

This phase II trial studies how well ruxolitinib phosphate works in treating older patients with acute myeloid leukemia in first complete remission after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Hematologic, Leukemia
II
Byrne, Michael
NCT03286530
VICCBMT1778

Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse / Refractory Multiple Myeloma

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse / refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Not Available
I
Cornell, Robert
NCT03269136
VICCHEMP1855

Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer

This study will enroll subjects with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A subjects will receive BGB-290; in Arm B subjects will receive placebo. The purpose of this study is to show that BGB-290 (versus placebo) will improve progression-free survival (PFS) in subjects with advanced or inoperable gastric cancer.
Not Available
III
Gibson, Mike
NCT03427814
VICCGI1892

Gabapentin Compared to Usual Care in Preventing Mucositis in Participants with Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

This randomized phase III trial studies how well gabapentin and usual care work compared to usual care alone in preventing inflammation of the mucous membranes (mucositis) in patients with stage III-IV head and neck cancer that are undergoing primary or subsequent (adjuvant) chemoradiation therapy. Radiation therapy to the head and neck may cause a burn involving the inside of the mouth, throat, and nasal passages, resulting in pain. Gabapentin may help prevent (or minimize) radiation-induced mucositis in patients with head and neck cancer.
Not Available
III
Smith, Derek
NCT02480114
VICCHN1541

Percutaneous Transhepatic Biliary Drainage or Endoscopic Retrograde Cholangiography in Treating Participants with Suspected Malignant Bile Duct Obstruction

Liver

This phase III trial studies how well percutaneous transhepatic biliary drainage works versus endoscopic retrograde cholangiography in treating participants with suspected cancerous (malignant) bile duct obstruction. Percutaneous transhepatic biliary drainage is a procedure that uses x-rays to guide a needle through the skin into the bile duct to allow for drainage of the blockage through external tubes. Endoscopic retrograde cholangiography is a procedure that combines the use of a lighted camera that goes down through the mouth and x-rays to diagnose and treat certain problems of the biliary ductal system, and permits drainage of the blockage through internal stents. It is not yet known whether percutaneous transhepatic biliary drainage or endoscopic retrograde cholangiography is most effective in treating participants with suspected malignant bile duct obstruction.
Liver
N/A
Yachimski, Patrick
NCT03172832
VICCGI17104

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: